SANUWAVE Amends Credit Agreement, Waives Coverage-Ratio Default for $5,000 Fee

SANUWAVE amended its credit agreement with JPMorgan Chase and lenders, waiving a coverage-ratio default for a $5,000 fee. The agreement tightened consent requirements for acquisitions and equity repurchases, and lowered two debt and investment limits from $500,000 to $250,000. The amendment was signed on October 28, 2026.

Original reporting
Published Oct 28, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SANUWAVE Amends Credit Agreement, Waives Coverage-Ratio Default for $5,000 Fee — source image
Decision brief

The 30-second read

$SNWVBearishLow
01

Why it matters

The amendment tightens financing terms but avoids an immediate default, likely resulting in modest stock pressure.

02

Market read

A small‑cap health‑tech firm disclosed a financing amendment that may slightly affect its share price.

03

What to watch

Potential upside if the waiver prevents a default that would have triggered a larger credit downgrade.

Relevance 5/10Novelty 5/10Timing: effective Oct 28 2026

Background

SANUWAVE Health, Inc. filed an 8‑K reporting an amendment and waiver to its credit agreement with JPMorgan Chase and participating lenders.

Company-level read

Ticker impact

$SNWVBearishMedium confidence
Context

SANUWAVE amended its credit agreement, waiving a coverage‑ratio default for a $5,000 fee and tightening consent requirements.

Expected impact

likely modest downside as investors price in tighter financing terms

Evidence & confidence

The $5,000 fee is trivial, but the reduced debt limits and stricter covenants signal tighter liquidity, which can pressure the stock.

Market effects

May prompt peers in the health‑tech financing space to review covenant structures.

Limited to U.S. small‑cap market; no broader regional effect.

Minimal global relevance.

Counterpoint

The amendment could be seen as a proactive step to avoid default, preserving credit standing.

Key entities

  • SANUWAVE Health, Inc.

    Issuer of the credit agreement amendment.

  • JPMorgan Chase Bank

    Primary lender granting the waiver.

Related articles

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMed

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.